Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo

Bulletin of the World Health Organization

Volumn 84, Issue 10, 2006, Pages 783-791

  Balasegaram, Manica ^a   Harris, Steve ^a   Checchi, Francesco ^b   Ghorashian, Sara ^a   Hamel, Catherine ^a   Karunakara, Unni ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ARTEMISININ; EFLORNITHINE; MELARSOPROL; PREDNISOLONE;

ANTIBIOTICS; DISEASE TREATMENT; HEALTH RISK; MULTIVARIATE ANALYSIS; TRYPANOSOMIASIS;

ADOLESCENT; ADULT; ARTICLE; CEREBROSPINAL FLUID CYTOLOGY; CONGO; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GAMBIA; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; RECURRENT DISEASE; RISK FACTOR; SHORT COURSE THERAPY; TRYPANOSOMA; TRYPANOSOMIASIS;

ADOLESCENT; ADULT; ANIMALS; CHILD; DEMOCRATIC REPUBLIC OF THE CONGO; DISEASE PROGRESSION; EFLORNITHINE; FEMALE; HUMANS; MALE; MELARSOPROL; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN;

AFRICA; CENTRAL AFRICA; CONGO; SUB-SAHARAN AFRICA;

EID: 33750243074     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.06.031955     Document Type: Article

References (18)

1. World Health Organization. Control and surveillance of African trypanosomiasis: report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1998;881:I-VI, 1-114.
2. Human African trypanosomiasis (sleeping sickness): epidemiological update. (PMID: 16673459). Wkly Epidemiol Rec 2006;81:71-80.
3. Abel PM, Kiala G, Loa V, Behrend M, Musolf J, Fleischmann H, et al. Retaking sleeping sickness control in Angola. Trop Med Int Health 2004;9:141-8.
4. Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, Jannin J, et al. Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet Infect Dis 2002;2:437-40.
5. Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 2001;6:390-400.
6. Milord F, Pepin J, Loko L, Ethier L, Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet 1992;340:652-5.
7. Croft SL, Barret MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005;21:508-12.
8. Pepin J, Khonde N, Maiso F, Doua F, Jaffar S, Ngampo S, et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ 2000;78:1284-95.
9. Schmid C, Richer M, Bilenge CM, Josenando T, Chappius F, Manthelot CR, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 2005;191:1922-31.
10. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 2004; 364:789-90.
11. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000;355:1419-25.
12. Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005;41:748-51.
13. Legros D, Evans S, Maiso F, Enyaru JC, Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999;93:439-42.
14. Brun R, Schumacher R, Schmid C, Kunz C, Burri C. The phenomenon of treatment failures in Human African Trypanosomiasis. Trop Med Int Health 2001;6:906-14.
15. Moore A, Burri C. Mission Report: information gathering and preimplementation for HATSENTINEL network in Angola and Congo DRC. Geneva: World Health Organization; 2002.
16. Ruiz JA, Simarro PP, Josenando T. Control of human African trypanosomiasis in the Quicama focus, Angola. Bull World Health Organ 2002;80:738-45.
17. Balasegaram M, Harris S, Checchi F, Hamel C, Karunakara U. Treatment outcomes and risk factors for relapse in patients with early stage human African trypanosomiasis (HAT) in the Republic of the Congo. Bull World Health Organ 2006. 2006;84:777-82.
18. Pepin J, Mpia B. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. Emerg Infect Dis 2005;11:921-7.